High Vista Strategies LLC Neurocrine Biosciences Inc Transaction History

High Vista Strategies LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $423,890 - $496,572	4,606 Added 122.27%	8,373 $889,000
Q2 2022 Aug 15, 2022	BUY	$75.79 - $100.07 $285,500 - $376,963	3,767 New	3,767 $367,000
Q4 2021 Feb 14, 2022	SELL	$79.65 - $106.22 $1.05 Million - $1.4 Million	-13,205 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$86.18 - $99.03 $436,501 - $501,586	5,065 Added 62.22%	13,205 $1.27 Million
Q2 2021 Aug 16, 2021	BUY	$89.43 - $102.27 $727,960 - $832,477	8,140 New	8,140 $792,000

626

94M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.2B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of High Vista Strategies LLC, based on Form 13F filings with the SEC.

Stay updated on High Vista Strategies LLC with notifications on news.